nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—HTR2A—attention deficit hyperactivity disorder	0.949	1	CbGaD
Cyclobenzaprine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.0057	0.392	CbGeAlD
Cyclobenzaprine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00303	0.209	CbGeAlD
Cyclobenzaprine—HTR2A—Serotonin receptors—HTR1B—attention deficit hyperactivity disorder	0.00165	0.0654	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.00123	0.0491	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.00121	0.0481	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.00104	0.0412	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.00102	0.0404	CbGpPWpGaD
Cyclobenzaprine—Doxepin—ADRA2C—attention deficit hyperactivity disorder	0.000771	0.0665	CrCbGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.000732	0.0291	CbGpPWpGaD
Cyclobenzaprine—Protriptyline—SLC6A4—attention deficit hyperactivity disorder	0.00073	0.063	CrCbGaD
Cyclobenzaprine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000705	0.0486	CbGeAlD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.000704	0.028	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.000681	0.0271	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Methylation—COMT—attention deficit hyperactivity disorder	0.000674	0.0268	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.000659	0.0262	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.000648	0.0258	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000642	0.0443	CbGeAlD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00064	0.0255	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.000616	0.0245	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.000596	0.0237	CbGpPWpGaD
Cyclobenzaprine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000596	0.0411	CbGeAlD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.000572	0.0228	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000554	0.022	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.000545	0.0217	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000538	0.0214	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000501	0.0199	CbGpPWpGaD
Cyclobenzaprine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000466	0.0321	CbGeAlD
Cyclobenzaprine—Benzphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000432	0.0372	CrCbGaD
Cyclobenzaprine—Benzphetamine—ADRA2A—attention deficit hyperactivity disorder	0.000423	0.0365	CrCbGaD
Cyclobenzaprine—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000421	0.0167	CbGpPWpGaD
Cyclobenzaprine—Cyproheptadine—DRD2—attention deficit hyperactivity disorder	0.000411	0.0354	CrCbGaD
Cyclobenzaprine—Chlorprothixene—DRD3—attention deficit hyperactivity disorder	0.00041	0.0353	CrCbGaD
Cyclobenzaprine—Chlorprothixene—DRD1—attention deficit hyperactivity disorder	0.000402	0.0347	CrCbGaD
Cyclobenzaprine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000383	0.0264	CbGeAlD
Cyclobenzaprine—Promazine—DRD4—attention deficit hyperactivity disorder	0.000372	0.0321	CrCbGaD
Cyclobenzaprine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000369	0.0254	CbGeAlD
Cyclobenzaprine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.00036	0.0248	CbGeAlD
Cyclobenzaprine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000354	0.0244	CbGeAlD
Cyclobenzaprine—Trimipramine—SLC6A3—attention deficit hyperactivity disorder	0.000352	0.0304	CrCbGaD
Cyclobenzaprine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000349	0.024	CbGeAlD
Cyclobenzaprine—Trimipramine—ADRA2A—attention deficit hyperactivity disorder	0.000345	0.0298	CrCbGaD
Cyclobenzaprine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000341	0.0235	CbGeAlD
Cyclobenzaprine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000337	0.0134	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000336	0.0231	CbGeAlD
Cyclobenzaprine—Doxepin—ADRA2A—attention deficit hyperactivity disorder	0.000329	0.0284	CrCbGaD
Cyclobenzaprine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000328	0.0226	CbGeAlD
Cyclobenzaprine—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000325	0.0129	CbGpPWpGaD
Cyclobenzaprine—Cyproheptadine—HTR2A—attention deficit hyperactivity disorder	0.000317	0.0274	CrCbGaD
Cyclobenzaprine—Promazine—DRD1—attention deficit hyperactivity disorder	0.000315	0.0271	CrCbGaD
Cyclobenzaprine—HTR2A—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.000293	0.0116	CbGpPWpGaD
Cyclobenzaprine—HTR2A—brain—attention deficit hyperactivity disorder	0.000293	0.0202	CbGeAlD
Cyclobenzaprine—Promazine—ADRA2A—attention deficit hyperactivity disorder	0.000292	0.0252	CrCbGaD
Cyclobenzaprine—Amitriptyline—HTR1B—attention deficit hyperactivity disorder	0.000287	0.0248	CrCbGaD
Cyclobenzaprine—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000285	0.0113	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.000284	0.0113	CbGpPWpGaD
Cyclobenzaprine—Chlorprothixene—DRD2—attention deficit hyperactivity disorder	0.000283	0.0244	CrCbGaD
Cyclobenzaprine—Nortriptyline—SLC6A4—attention deficit hyperactivity disorder	0.00028	0.0241	CrCbGaD
Cyclobenzaprine—Amitriptyline—DRD3—attention deficit hyperactivity disorder	0.000279	0.0241	CrCbGaD
Cyclobenzaprine—Nortriptyline—DRD2—attention deficit hyperactivity disorder	0.000278	0.024	CrCbGaD
Cyclobenzaprine—CYP2D6—brain—attention deficit hyperactivity disorder	0.000267	0.0184	CbGeAlD
Cyclobenzaprine—Trimipramine—SLC6A4—attention deficit hyperactivity disorder	0.000263	0.0227	CrCbGaD
Cyclobenzaprine—Trimipramine—DRD2—attention deficit hyperactivity disorder	0.000262	0.0226	CrCbGaD
Cyclobenzaprine—Imipramine—SLC6A3—attention deficit hyperactivity disorder	0.000261	0.0225	CrCbGaD
Cyclobenzaprine—Amitriptyline—ADRA2A—attention deficit hyperactivity disorder	0.000254	0.0219	CrCbGaD
Cyclobenzaprine—Promethazine—DRD2—attention deficit hyperactivity disorder	0.000252	0.0218	CrCbGaD
Cyclobenzaprine—Doxepin—SLC6A4—attention deficit hyperactivity disorder	0.000251	0.0217	CrCbGaD
Cyclobenzaprine—Doxepin—DRD2—attention deficit hyperactivity disorder	0.00025	0.0215	CrCbGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000246	0.00977	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000238	0.00947	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000233	0.00928	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000232	0.00921	CbGpPWpGaD
Cyclobenzaprine—Promazine—DRD2—attention deficit hyperactivity disorder	0.000222	0.0191	CrCbGaD
Cyclobenzaprine—Chlorprothixene—HTR2A—attention deficit hyperactivity disorder	0.000219	0.0189	CrCbGaD
Cyclobenzaprine—Nortriptyline—HTR2A—attention deficit hyperactivity disorder	0.000215	0.0185	CrCbGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000211	0.00841	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000204	0.00811	CbGpPWpGaD
Cyclobenzaprine—Trimipramine—HTR2A—attention deficit hyperactivity disorder	0.000202	0.0175	CrCbGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0002	0.00795	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000197	0.00781	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.000197	0.00781	CbGpPWpGaD
Cyclobenzaprine—Imipramine—SLC6A4—attention deficit hyperactivity disorder	0.000195	0.0168	CrCbGaD
Cyclobenzaprine—Promethazine—HTR2A—attention deficit hyperactivity disorder	0.000195	0.0168	CrCbGaD
Cyclobenzaprine—Imipramine—DRD2—attention deficit hyperactivity disorder	0.000194	0.0168	CrCbGaD
Cyclobenzaprine—Amitriptyline—SLC6A4—attention deficit hyperactivity disorder	0.000194	0.0167	CrCbGaD
Cyclobenzaprine—Amitriptyline—DRD2—attention deficit hyperactivity disorder	0.000193	0.0167	CrCbGaD
Cyclobenzaprine—Doxepin—HTR2A—attention deficit hyperactivity disorder	0.000193	0.0166	CrCbGaD
Cyclobenzaprine—Promazine—HTR2A—attention deficit hyperactivity disorder	0.000171	0.0148	CrCbGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000162	0.00643	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000155	0.00618	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000153	0.00607	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000152	0.00605	CbGpPWpGaD
Cyclobenzaprine—Imipramine—HTR2A—attention deficit hyperactivity disorder	0.00015	0.0129	CrCbGaD
Cyclobenzaprine—Amitriptyline—HTR2A—attention deficit hyperactivity disorder	0.000149	0.0129	CrCbGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000148	0.00588	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000143	0.00567	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000141	0.00562	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000139	0.00551	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000131	0.00522	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000131	0.0052	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000129	0.00514	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000127	0.00506	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000125	0.00497	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000124	0.00491	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000121	0.00482	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000119	0.00473	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000118	0.0047	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000115	0.00458	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000113	0.00448	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000109	0.00434	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000107	0.00426	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000106	0.00421	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000106	0.00419	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	9.98e-05	0.00397	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	9.86e-05	0.00392	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.22e-05	0.00367	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	8.78e-05	0.00349	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.6e-05	0.00342	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.57e-05	0.00341	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	8.52e-05	0.00339	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	8.52e-05	0.00339	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.3e-05	0.0033	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	8.17e-05	0.00325	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.16e-05	0.00325	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	8.11e-05	0.00322	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.06e-05	0.0032	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	8.05e-05	0.0032	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.97e-05	0.00317	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.81e-05	0.00311	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.51e-05	0.00299	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.02e-05	0.00279	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.92e-05	0.00275	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.87e-05	0.00273	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.82e-05	0.00271	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	6.39e-05	0.00254	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.96e-05	0.00237	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.48e-05	0.00218	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.41e-05	0.00215	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.34e-05	0.00212	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.3e-05	0.00211	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.27e-05	0.00209	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.21e-05	0.00207	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.84e-05	0.00193	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.73e-05	0.00188	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.71e-05	0.00187	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.69e-05	0.00187	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.61e-05	0.00183	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.61e-05	0.00183	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.56e-05	0.00181	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.53e-05	0.0018	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.4e-05	0.00175	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.26e-05	0.00169	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.24e-05	0.00169	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.19e-05	0.00167	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.14e-05	0.00164	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.85e-05	0.00153	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.34e-05	0.00133	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.2e-05	0.00127	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.83e-05	0.00112	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.8e-05	0.00111	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.6e-05	0.00103	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.52e-05	0.001	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.47e-05	0.000984	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.44e-05	0.000972	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.3e-05	0.000916	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.3e-05	0.000916	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.28e-05	0.000905	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.27e-05	0.000902	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.18e-05	0.000868	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.11e-05	0.000838	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.95e-05	0.000776	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.95e-05	0.000776	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.92e-05	0.000764	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.84e-05	0.000733	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.79e-05	0.00071	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.75e-05	0.000697	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.56e-05	0.000621	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.51e-05	0.000599	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.51e-05	0.000599	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.49e-05	0.000591	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.48e-05	0.000589	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.4e-05	0.000555	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.39e-05	0.000551	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.38e-05	0.000548	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.2e-05	0.000479	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	1.18e-05	0.00047	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	1.17e-05	0.000467	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.15e-05	0.000456	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.14e-05	0.000453	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	9.13e-06	0.000363	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	9.07e-06	0.00036	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.45e-06	0.000336	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	5.99e-06	0.000238	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	5.07e-06	0.000202	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.92e-06	0.000156	CbGpPWpGaD
